Core Viewpoint - Tonix Pharmaceuticals is advancing TNX-1900, an intranasal formulation of oxytocin, as a potential treatment for migraine and craniofacial pain, targeting a distinct pathway compared to existing CGRP inhibitors [1][2][4]. Group 1: TNX-1900 Development - The first participant has been dosed in a Phase 1 study to evaluate TNX-1900's effect on trigeminal nerve-mediated vasodilation in healthy female volunteers [1]. - TNX-1900 is designed to block the release of calcitonin gene-related peptide (CGRP), a key vasodilator involved in migraine pathogenesis [2][4]. - The study utilizes Laser Speckle Contrast Imaging (LSCI) for real-time dermal blood flow measurements, enhancing the understanding of TNX-1900's effects [2][4]. Group 2: Mechanism of Action - TNX-1900 operates through a unique mechanism by binding to oxytocin receptors in the trigeminal ganglion, inhibiting CGRP release, which differs from CGRP receptor antagonists [4][5]. - The formulation includes magnesium to enhance oxytocin receptor binding and provide analgesic effects in craniofacial pain [5]. Group 3: Migraine Overview - Migraine affects approximately 1.2 billion individuals globally, with around 39 million in the U.S., including 4 million experiencing chronic migraines [3]. - The condition is characterized by severe headaches, often accompanied by nausea and sensitivity to light and sound [3]. Group 4: Company Background - Tonix Pharmaceuticals is a biotechnology company focused on CNS and immunology treatments, with a portfolio that includes products for migraine and other conditions [10]. - The company is also developing TNX-2900 for Prader-Willi syndrome and has a pipeline for various other health issues, including binge eating disorder and insulin resistance [10].